Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald
Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald
Stock analysts at Cantor Fitzgerald initiated coverage on shares of Editas Medicine (NASDAQ:EDIT – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set an "overweight" rating on the stock.
股票分析師在康托·菲茨杰拉德啟動覆蓋的股份 編輯醫學 (納斯達克:編輯-獲得評級) 在星期二發布的報告中，飛報告。經紀公司對股票設定了「超重」評級。
EDIT has been the topic of a number of other reports. Bank of America decreased their target price on Editas Medicine from $18.00 to $15.00 and set a "neutral" rating on the stock in a report on Friday, November 18th. Chardan Capital lowered their price target on Editas Medicine from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Thursday, November 17th. Evercore ISI lowered their price target on Editas Medicine to $8.00 in a report on Monday, November 21st. Royal Bank of Canada lowered their price target on Editas Medicine from $32.00 to $14.00 and set a "sector perform" rating on the stock in a report on Friday, November 18th. Finally, Morgan Stanley lowered their price target on Editas Medicine from $8.00 to $7.00 and set an "underweight" rating on the stock in a report on Tuesday, January 24th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $16.86.
編輯一直是許多其他報告的主題。美國銀行將 Editas 醫藥的目標價格從 18.00 美元降至 15.00 美元，並在 11 月 18 日（星期五）的一份報告中設定了該股票的「中性」評級。查丹資本將 Editas 醫藥的價格目標從 $43.00 降至 35.00 美元，並在 11 月 17 日（星期四）的報告中設置了股票的「買入」評級。永可 ISI 在 11 月 21 日星期一的一份報告中將其對 Editas 醫藥的價格目標降低至 8.00 美元。加拿大皇家銀行將 Editas 醫藥的價格目標從 32.00 美元降至 14.00 美元，並在 11 月 18 日（星期五）的一份報告中設定了該股票的「行業表現」評級。最後，摩根士丹利將 Editas Medine 的價格目標從 8.00 美元降至 7.00 美元，並在 1 月 24 日（星期二）的一份報告中設定了該股票的「體重不足」評級。三位研究分析師對該股票進行了賣出評級，八人發出了持有評級，五名分析師對該公司的股票給予了買入評級。根據 MarketBeat 的數據，該公司的平均評級為「持有」，平均價格目標為 16.86 美元。
Editas Medicine Trading Up 5.8 %
編輯醫藥交易上升 5.8%
Shares of NASDAQ EDIT traded up $0.54 during mid-day trading on Tuesday, reaching $9.89. The company had a trading volume of 2,458,061 shares, compared to its average volume of 1,987,798. The stock has a market cap of $680.04 million, a PE ratio of -3.34 and a beta of 1.90. The company has a 50-day moving average price of $9.23 and a two-hundred day moving average price of $12.51. Editas Medicine has a 1-year low of $7.70 and a 1-year high of $21.59.
納斯達克編輯的股票在周二中間交易期間交易上漲了 0.54 美元，達到 9.89 美元。該公司的交易量為 2,458,061 股，相比其平均交易量為 1,987,798 股。該股的市值為 680.04 萬美元，私募股權比率為 -3.34，測試版為 1.90。該公司的 50 天移動平均價為 9.23 美元，兩百天移動平均價為 12.51 美元。編輯醫學有一年的低點 7.70 美元和 1 年高點 21.59 美元。
Hedge Funds Weigh In On Editas Medicine
對沖基金權衡編輯醫學
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Total Clarity Wealth Management Inc. acquired a new position in shares of Editas Medicine in the 2nd quarter worth approximately $27,000. Covestor Ltd boosted its holdings in shares of Editas Medicine by 9,693.3% in the 1st quarter. Covestor Ltd now owns 1,469 shares of the company's stock worth $28,000 after acquiring an additional 1,454 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Editas Medicine in the 2nd quarter worth approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Editas Medicine in the 1st quarter worth approximately $44,000. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Editas Medicine in the 3rd quarter worth approximately $48,000. 69.67% of the stock is currently owned by institutional investors.
機構投資者和對沖基金最近增加或減少了他們在公司的股份。全清財富管理公司在第二季度收購了 Editas 醫藥股份的新位置，價值約為 27,000 美元。科夫斯特有限公司在第一季度將其對 Editas 醫藥股份的持有量提高了 9,693.3％。科維斯特有限公司現在擁有該公司股票的 1,469 股，價值 28,000 美元，在上一季度額外收購了 1,454 股。羅素投資集團有限公司於第二季度收購了 Editas 醫藥股份的新職位，價值約 32,000 美元。昆特科技有限公司在第一季度收購了 Editas 醫藥股份的新位置，價值約為 44,000 美元。最後，大西部生活保證有限公司。可以在第三季度收購 Editas 醫藥股份的新頭寸，價值約為 48,000 美元。6967％ 的股票目前由機構投資者擁有。
About Editas Medicine
關於編輯醫學
(Get Rating)
(取得評分)
Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Editas 醫學公司從事基因組編輯技術的開發和商業化。其技術包括聚集，定期間隔的短回文重複（CRISPR）和 CRISPR 相關蛋白質 9（Cas9）。該公司由馮章，珍妮弗 ·A· 杜德納，喬治麥當勞教堂，J.
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Editas Medicine (EDIT)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 獲取有關編輯醫學研究報告的免費副本（編輯）
- Verizon 公司, 憲章趨勢在過去一個月較高:他們現在買?
- 股息國王塞斯科：在下跌的購買
- 天才集團股票上漲 1,600% 是否合理？
- 經過進一步審查，投資者喜歡埃克森美孚的收益
- 卡特彼勒會挖掘其方式到另一個購買機會嗎？
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Editas 醫學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Editas Medicine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。